Abstract
Aim: Development of multi drug resistance and dose limiting cardiotoxicity are hindering the use of Doxorubicin (Dox) in clinical settings. Augmented dox efflux induced by lung resistance protein (LRP) over expression has been related to multi drug resistance phenotype in various cancers. An alkaloid from lotus, Neferine (Nef) shows both anticancer and cardioprotective effects. Here, we have investigated the interconnection between nuclear factor erythroid-derived 2-like 2 (NRF2) and LRP in Dox resistance and how Nef can overcome Dox resistance in lung cancer cells by altering this signaling.Methods: Anti-proliferative and apoptotic-inducing effects of Nef and Dox combination in Parental and Dox resistant lung cancer cells were determined in monolayers and 3D spheroids. Intracellular Dox was analyzed using flow cytometry, siRNA knockdown and western blot analysis were used to elucidate NRF2-LRP crosstalk mechanism.Results: We observed that the Dox resistant lung cancer cells expressed higher levels of LRP, reduced glutathione (GSH) and NRF2. Combination of Dox and Nef induced apoptosis, leads to reactive oxygen species (ROS) generation, GSH depletion and reduction in LRP levels contributing to higher intracellular and intranuclear Dox accumulation. The use of N-acetylcysteine and knockdown studies confirmed an important role of ROS and NRF2 in LRP down regulation. Presence of NRF2 binding sites in LRP is support of direct interaction between LRP and NRF2.Conclusion: Nef sensitizes lung cancer cells to Dox by increasing intracellular and/or intra nuclear Dox accumulation via LRP down regulation. This is mediated by redox regulating NRF2. This decoded crosstalk mechanism reinforces the role of NRF2 and LRP in Dox resistance and as an important anticancer target.
Highlights
Lung cancer is the leading cause of mortality worldwide
We observed that the Dox resistant lung cancer cells expressed higher levels of lung resistance protein (LRP), reduced glutathione (GSH) and nuclear factor erythroid-derived 2-like 2 (NRF2)
The use of N-acetylcysteine and knockdown studies confirmed an important role of reactive oxygen species (ROS) and NRF2 in LRP down regulation
Summary
Postoperative chemotherapy is an important adjuvant treatment in non-small cell lung cancer (NSCLC). Tumor recurrence often occurs after chemotherapy due to multidrug resistance, and is a major impediment in lung cancer management[1,2,3]. From its discovery and introduction in several investigational and approved chemotherapy regimens, Dox has contributed to improved life expectancy of countless cancer patients[5]. The clinical efficacy and usefulness of Dox-based treatment regimens is still limited because of dose-limiting toxicity and induction of drug-resistance overtime[6]. In advanced NSCLCs, Dox treatment provides only an overall response rate of 30%-50% and most of the patients develop resistance towards Dox treatment[7]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
